Boehringer, Teva Sued Again Over Deal To Delay Generic

Law360, New York (January 6, 2014, 4:12 PM EST) -- Teva Pharmaceuticals USA Inc. and Boehringer Ingelheim Pharmaceuticals Inc. were hit Monday with another proposed antitrust class action, this in Minnesota federal court, over an alleged pay-for-delay deal that kept a generic form of an anti-stroke medication off the market.

A health and welfare fund of the International Union of Painters and Allied Trades said Monday that indirect purchasers of the stroke-risk-reducing drug Aggrenox paid artificially high prices for it because of an anti-competitive deal between Boehringer and Teva subsidiary Barr Pharmaceuticals Inc.

It was at...
To view the full article, register now.